Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Nyxoah S.A.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Nyxoah S.A. (“Nyxoah” or “the Company”) (NASDAQ: NYXH). Investors who purchased Nyxoah securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Nyxoah has violated federal securities laws.
Investigation Details
On March 25, 2025, Nyxoah issued a press release “announcing that the U.S. Food and Drug Administration (FDA) has issued an Approvable Letter regarding the Company’s Pre-Market Approval (PMA) application for the Genio® system”, adding that the letter “means that Nyxoah’s application for marketing the device in the United States substantially meets the requirements of the Federal Food, Drug and Cosmetic Act and the FDA’s PMA implementing regulations … and the FDA will approve the application subject to satisfactory completion of a manufacturing facilities, methods and controls review.” Analysts noted that the Company’s announcement will likely result in a delay in Genio’s commercial launch. Following this news, Nyxoah stock dropped more than 21.3% the next day.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Nyxoah securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
NYXH — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”